1. Home
  2. MRIN vs ENTO Comparison

MRIN vs ENTO Comparison

Compare MRIN & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRIN
  • ENTO
  • Stock Information
  • Founded
  • MRIN 2006
  • ENTO 2014
  • Country
  • MRIN United States
  • ENTO United States
  • Employees
  • MRIN N/A
  • ENTO N/A
  • Industry
  • MRIN EDP Services
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRIN Technology
  • ENTO Health Care
  • Exchange
  • MRIN Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • MRIN 1.9M
  • ENTO 1.7M
  • IPO Year
  • MRIN 2013
  • ENTO 2016
  • Fundamental
  • Price
  • MRIN $0.97
  • ENTO $0.42
  • Analyst Decision
  • MRIN
  • ENTO
  • Analyst Count
  • MRIN 0
  • ENTO 0
  • Target Price
  • MRIN N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • MRIN 5.0M
  • ENTO 131.6K
  • Earning Date
  • MRIN 05-23-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • MRIN N/A
  • ENTO N/A
  • EPS Growth
  • MRIN N/A
  • ENTO N/A
  • EPS
  • MRIN N/A
  • ENTO N/A
  • Revenue
  • MRIN $16,707,999.00
  • ENTO N/A
  • Revenue This Year
  • MRIN N/A
  • ENTO N/A
  • Revenue Next Year
  • MRIN N/A
  • ENTO N/A
  • P/E Ratio
  • MRIN N/A
  • ENTO N/A
  • Revenue Growth
  • MRIN N/A
  • ENTO N/A
  • 52 Week Low
  • MRIN $0.41
  • ENTO $0.19
  • 52 Week High
  • MRIN $3.53
  • ENTO $3.16
  • Technical
  • Relative Strength Index (RSI)
  • MRIN 49.69
  • ENTO 54.54
  • Support Level
  • MRIN $0.50
  • ENTO $0.37
  • Resistance Level
  • MRIN $1.62
  • ENTO $0.44
  • Average True Range (ATR)
  • MRIN 0.15
  • ENTO 0.04
  • MACD
  • MRIN 0.04
  • ENTO 0.01
  • Stochastic Oscillator
  • MRIN 42.48
  • ENTO 47.58

About MRIN Marin Software Incorporated

Marin Software Inc provides a cloud-based digital advertising management solution for search, display, social, and mobile advertising channels to improve financial performance, realize efficiencies and time savings, and improve business decisions. The company's enterprise marketing software platform is offered as an integrated software-as-a-service (SaaS) solution for advertisers and agencies. Its software solution is designed to help its customers measure the effectiveness of their advertising campaigns through its reporting and analytics capabilities; and manage and execute campaigns through its user interface and underlying technology that streamlines and automates functions. All the business activity of the firm is functioned through the geographical regions of The United States.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: